Table 1.
Clinical characteristics of the study participants.
| Healthy KTR | KTR with NMSC |
KTR developing NMSC |
|
|---|---|---|---|
| n = 123 | n = 55 | n = 6 | |
| Female | 53 (43) | 15 (28) | 2 (33) |
| Age (y) | 52 (23-82) | 66 (35-82) | 53.5 (41-71) |
| Time on dialysis (y) | 2.7 (0-12.8) | 3.6 (0-14.7) | 1.9 (0-9.1) |
| Deceased donor kidney | 63 (51) | 36 (67) | 2 (33) |
| Time since transplantation (y) | 6.1 (0.2-28.4) | 12.8 (3.8-35.9) | 4.0 (0.4-8.0) |
| Treated for graft rejection | 41 (33) | 28 (52) | 1 (17) |
| Immunosuppression | |||
| Tac + MPA + Steroid | 40 (33) | 17 (31) | 3 (50) |
| CsA + MPA + Steroid | 52 (42) | 14 (26) | 2 (33) |
| mTOR-inh. + MPA + Steroid | 6 (5) | 4 (7) | 1 (17) |
| Azathioprine + others | 4 (3) | 5 (9) | 0 (0) |
| Belatacept + others | 2 (2) | 4 (7) | 0 (0) |
| Others | 19 (15) | 10 (19) | 0 (0) |
| NMSC | |||
| Squamous cell carcinoma | 24 (44) | 2 (33) | |
| Actinic keratosis | 18 (33) | 4 (67) | |
| Bowen disease | 16 (30) | 3 (50) | |
| Basal cell carcinoma | 32 (59) | 2 (33) | |
| Serum creatinine (mg/dl) | 1.26 (0.63-1.90) | 1.36 (0.60-2.83) | 1.15 (0.88-1.75) |
| Urea (mg/dl) | 40 (14-84) | 58 (15-153) | 37 (25-66) |
| CKD-EPI GFR (ml/min/1.73m²) | 60.9 (32.3-114.8) | 52.8 (22.7-97.7) | 66.3 (39.7-84.8) |
| C-reactive protein (mg/l) | <2.0 (<2.0-4.7) | 2.2 (<2.0-32.8) | <2.0 (<2.0-<2.0) |
Categorial variables are presented as number (percentage), continuous variables as median (minimum-maximum). CKD-EPI GFR, chronic kidney disease epidemiology collaboration estimated glomerular filtration rate; CsA, ciclosporin A; KTR, kidney transplant recipients; MPA, mycophenolic acid; mTOR-inh., mechanistic target of rapamycin-inhibitor; NMSC, non-melanoma skin cancer; Tac, tacrolimus.